Sign for Notice Everyday    Sign Up| Sign In| Link|

Our Sponsors

  • ESTA - Electronic System for Travel Authorization
Receive Latest News

Share Us

PRODUCT INFORMATION FOR MEDICINAL PRODUCTS 2017 - Seminar on Product Information for Medicinal Products in the EU 2017

View: 442

Website | Edit Freely

Category FDA;Online Regulatory Compliance Training;FDA Regulations Training;Compliance Seminars

Deadline: June 17, 2017 | Date: June 19, 2017-June 20, 2017

Venue/Country: Hilton Zurich Airport,Hohenbuhlstrasse 10, 8152 Op, Switzerland

Updated: 2017-02-17 15:10:33 (GMT+9)

Call For Papers - CFP

Course "Product Information for Medicinal Products in the EU" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.


Regular review and monitoring of product information for medicines is important, to support awareness of relevant updates/changes which may affect prescribing, dispensing, administration or monitoring practices. It is also important that patients and caregivers, as appropriate, are made aware of the information contained in the Package Leaflet (PL) and should be encouraged to read it prior to and during their treatment.

The PL reflects the more comprehensive information described in the SmPC, but is required to be presented in an abbreviated and easyto-read format for patients.

The SmPC provides the basis of information for healthcare professionals to use a medicine safely, effectively and in the most appropriate manner. It is also a legal document, agreed between the Authorities and the relevant pharmaceutical company.

The format and content of the SmPC is laid down in EU/national legislation and regulatory guidance documents. Use of a medicine outside the conditions/ recommendations described in the SmPC falls under the responsibility of the healthcare professional.

It is important to note that the SmPC is not intended to provide general advice on the treatment of particular medical conditions. On the other hand, specific aspects of the treatment related to use of the medicine, or its effects may be mentioned. Similarly, general advice on administration procedures is not included, but any advice specific to the medicine concerned will be included, if appropriate.

The PL is drawn up in accordance with the SmPC and is subject to user-testing to ensure its ease of readability by patients/consumers. It plays an essential part in supporting the safe and effective use of a medicine by a patient. Consequently, it is important that a PL is provided each time a product is dispensed. Patients and care-givers should be encouraged to read the current version of the PL that accompanies their medicine(s) and to discuss any relevant concerns with a healthcare professional involved in their care.

Why should you attend:

Product Information is a key part of the marketing authorisation of all medicines authorised in the European Union

The product information is comprised of the Summary of Product Characteristics (SmPC) and the PL. These documents are issued when a medicine is first licensed for use and are reviewed and updated as necessary throughout the lifetime of a medicine, to reflect the current state of knowledge of the medicine and the risks associated with its use. The SmPC is mainly intended for use by healthcare professionals

SmPCs are also the basis for the preparation of package leaflets, so are important documents in enabling information on medicines to reach patients.

The labelling and package leaflet are important tools to achieve correct use of the medicinal product. Marketing Authorisation Holders (MAHs) are required to ensure that current versions of the labelling and package leaflet are used when medicines are supplied to pharmacies.

Areas Covered in the Session:

• SmPC

• Package Leaflet

• Labelling

• Readability testing

Who Will Benefit:

• Regulatory Affairs personnel involved in Product Information of medicinal products in the EU


Day 1 Schedule

Lecture 1:

The SmPC

• The role of the SmPC (including use as Pharmacovigilance Document)

• Where does the information come from?

o Structure of the Common Technical Document

o Structure of SmPC in reference to difference Modules

o Structure of SmPC in reference to departmental responsibilities (PV, Clinical, Quality, etc.)

o Relationship between Modules, SmPC, PIL, Labelling - the last three being the only key information seen by general public / med practitioners

• How to write an SmPC from scratch

• Presentation and discussion of key guidance documents (including templates) from EMA/CHMP

• The importance of writing the SmPC so that it will be precise, exact, readable, and unambiguous

• Clarifying the therapeutic indications

• Listing contraindications

• Defining the warnings and precautions for use

• Highlighting potential drug interactions

• Defining instructions for proper use, improving tolerance to medicines by communicating necessary safety information and avoiding untoward effects

• Describing adverse reactions from clinical studies and spontaneous reporting and how it may influence pharmacovigilance

• Describing instructions for storage, shelf life and in use stability claims,

• Timing of reporting the date of last revision

• Translations

• The package leaflet

• Relationship between SmPC / Package Leaflet

• differences

• what is reflected where and in what format?

• The perception of risk of a medicinal product

• Guidelines for package leaflets

• Combining package leaflets for different pharmaceutical forms, presentations and strengths of a medicinal product

• The package leaflet as a marketing tool, what is allowed?

Lecture 2:

Practical exercises: Successfully working through the Regulations

In this session, participants will be able to analyse the regulatory requirements and will gain an in-depth knowledge of how to meet them. The emphasis will be on grasping what information is required. This is a unique opportunity for the participants to ensure they fully understand and comply with the regulations in place.

Lecture 3:

Participants will work on the following points:

• Understanding what must be included in your Patient Information Leaflets (PLs) with a focus on safety

• Overcoming the special challenges when drafting the safety sections on contraindications, warnings and precautions

Lecture 4:

Practical exercise 1

• Writing a package leaflet, based on an SmPC

Lecture 5:

Practical exercise 2

• Improving a package leaflet, making it more clear and patient-friendly

Lecture 6:


• Relationship between SmPC / Labelling

• Requirements for labels

• Minimum information on small labels

• Additional secondary packaging, e.g. Lilly contraceptives

• Labelling as a marketing tool, what is allowed?

Lecture 7:

Practical exercise 3

• Writing the label text, based on an SmPC

Day 2 Schedule

Lecture 1:

Examining the legal issues surrounding the European regulations

• How must safety information be presented to the patient that would prevent very severe consequences such as foetus deformity - be included in leaflets?

• How does a company manage this by region?

• How often should a SmPC leaflet be reviewed? Relationship with PSURs.

• Risk-Management Plans and how they affect product information

Lecture 2:

Readability Testing

• Legal requirements

• Language requirements

• Where to test

• Pitfalls in developing a test

• Interviewing focus groups

• Bridging tests

• Inclusion and exclusion criteria

Lecture 3:

Practical exercise 4

• Conduct readability testing with the participants

Lecture 4:

Product Information during the registration procedures

• Before submission

• Steps to consider after submission and before marketing approval

• What to agree to and what not to agree to when negotiating with the Health Authorities

• What to do after CHMP opinion until EU Commission authorisation

Lecture 5:

Product Information after approval

• Overview of Variations

• Variations involving Product Information

• Variations for generic/hybrid/biosimilar products

• Variations following referrals

• Implementation of Pharmacovigilance requirements

• What to do with editorial changes?

• When to submit the translations

• Article 61(3) Notification

Lecture 6:

International situation

• Comparing US labelling, the Package Insert; also the complementary Medication Guide for the high risk drugs under a REMS


Adriaan Fruijtier

Regulatory Affairs Consultant, CATS Consultants GmbH

Adriaan Fruijtier has graduated as a pharmacist at the University of Utrecht, The Netherlands.

He is currently Director Regulatory Affairs at CATS Consultants. Until March 2004 he has been Head of the Oncology Group within Global Regulatory Affairs at Bayer AG, Wuppertal, Germany, and Bayer Corporation, West Haven, CT, USA. Between 2001 and 2003 he was Director of Regulatory Affairs at Micromet AG, a biotech company in Munich, Germany. Prior to joining Micromet he has worked during four years as a Project Manager for Oncology Projects at the European Medicines Agency in London, United Kingdom.

He joined the European Medicines Agency from Novartis AG, Basel, Switzerland, where he was Regulatory Affairs Project Manager in the Oncology group in 1996 and 1997.

Before 1996 he was Head of Drug Regulatory Affairs for six years at Ciba-Geigy in the Netherlands, and has worked as Manager Regulatory Affairs at Glaxo, also in the Netherlands.

Location: Zurich, Switzerland Date: June 19th & 20th, 2017 and Time: 9:00 AM to 6:00 PM

Venue: Hilton Zurich Airport

Address: Hohenbuhlstrasse 10, 8152 Opfikon-Glattbrugg, Switzerland. +41 44 828 50 50


Price: $1,695.00 (Seminar Fee for One Delegate)

Register for 5 attendees Price: $5085.00 $8,475.00 You Save: $3390.00 (40%)*

Until May 10, Early Bird Price: $1,695.00 From May 11 to June 17, Regular Price: $1,895.00

Quick Contact:

NetZealous DBA as GlobalCompliancePanel

Phone: 1-800-447-9407

Fax: 302-288-6884



Registration Link -

Follow on LinkedIn:

Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.